These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 16436501

  • 1. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
    Kakui N, Tanaka J, Tabata Y, Asai K, Masuda N, Miyara T, Nakatani Y, Ohsawa F, Nishikawa N, Sugai M, Suzuki M, Aoki K, Kitaguchi H.
    J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
    [Abstract] [Full Text] [Related]

  • 2. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
    Kanatani A, Ishihara A, Iwaasa H, Nakamura K, Okamoto O, Hidaka M, Ito J, Fukuroda T, MacNeil DJ, Van der Ploeg LH, Ishii Y, Okabe T, Fukami T, Ihara M.
    Biochem Biophys Res Commun; 2000 May 27; 272(1):169-73. PubMed ID: 10872822
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT, Hogan JB, Leahy CL, Flowers SC, Stanley JA, Ortiz AA, Poindexter GS.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):224-32. PubMed ID: 18573246
    [Abstract] [Full Text] [Related]

  • 4. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents.
    Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN.
    Br J Pharmacol; 1998 Oct 20; 125(3):549-55. PubMed ID: 9806339
    [Abstract] [Full Text] [Related]

  • 5. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.
    Kanatani A, Kanno T, Ishihara A, Hata M, Sakuraba A, Tanaka T, Tsuchiya Y, Mase T, Fukuroda T, Fukami T, Ihara M.
    Biochem Biophys Res Commun; 1999 Dec 09; 266(1):88-91. PubMed ID: 10581170
    [Abstract] [Full Text] [Related]

  • 6. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.
    Criscione L, Rigollier P, Batzl-Hartmann C, Rüeger H, Stricker-Krongrad A, Wyss P, Brunner L, Whitebread S, Yamaguchi Y, Gerald C, Heurich RO, Walker MW, Chiesi M, Schilling W, Hofbauer KG, Levens N.
    J Clin Invest; 1998 Dec 15; 102(12):2136-45. PubMed ID: 9854049
    [Abstract] [Full Text] [Related]

  • 7. Direct evidence that stimulation of neuropeptide Y Y5 receptor activates hypothalamo-pituitary-adrenal axis in conscious rats via both corticotropin-releasing factor- and arginine vasopressin-dependent pathway.
    Kakui N, Kitamura K.
    Endocrinology; 2007 Jun 15; 148(6):2854-62. PubMed ID: 17363455
    [Abstract] [Full Text] [Related]

  • 8. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
    Mullins D, Adham N, Hesk D, Wu Y, Kelly J, Huang Y, Guzzi M, Zhang X, McCombie S, Stamford A, Parker E.
    Eur J Pharmacol; 2008 Dec 28; 601(1-3):1-7. PubMed ID: 18976648
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
    Dumont Y, Thakur M, Beck-Sickinger A, Fournier A, Quirion R.
    Neuropeptides; 2004 Aug 28; 38(4):163-74. PubMed ID: 15337369
    [Abstract] [Full Text] [Related]

  • 11. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
    Torrens A, Mas J, Port A, Castrillo JA, Sanfeliu O, Guitart X, Dordal A, Romero G, Fisas MA, Sánchez E, Hernández E, Pérez P, Pérez R, Buschmann H.
    J Med Chem; 2005 Mar 24; 48(6):2080-92. PubMed ID: 15771450
    [Abstract] [Full Text] [Related]

  • 12. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
    Henry M, Ghibaudi L, Gao J, Hwa JJ.
    Obes Res; 2005 Jan 24; 13(1):36-47. PubMed ID: 15761161
    [Abstract] [Full Text] [Related]

  • 13. Potent and selective tools to investigate neuropeptide Y receptors in the central and peripheral nervous systems: BIB03304 (Y1) and CGP71683A (Y5).
    Dumont Y, Cadieux A, Doods H, Fournier A, Quirion R.
    Can J Physiol Pharmacol; 2000 Feb 24; 78(2):116-25. PubMed ID: 10737674
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
    Cabrele C, Beck-Sickinger AG.
    J Pept Sci; 2000 Mar 24; 6(3):97-122. PubMed ID: 10759209
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.
    Murakami Y, Hara H, Okada T, Hashizume H, Kii M, Ishihara Y, Ishikawa M, Shimamura M, Mihara S, Kato G, Hanasaki K, Hagishita S, Fujimoto M.
    J Med Chem; 1999 Jul 15; 42(14):2621-32. PubMed ID: 10411482
    [Abstract] [Full Text] [Related]

  • 18. Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms.
    Gao J, Ghibaudi L, Hwa JJ.
    Am J Physiol Endocrinol Metab; 2004 Oct 15; 287(4):E706-11. PubMed ID: 15187000
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system.
    Pons J, Kitlinska J, Ji H, Lee EW, Zukowska Z.
    Can J Physiol Pharmacol; 2003 Feb 15; 81(2):177-85. PubMed ID: 12710532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.